New Antibody-Drug Conjugate Improves Survival in Advanced Endometrial Cancer

Results from the international Phase III clinical trial TroFuse-005/ENGOT-en23/GOG-3095, published in The Lancet, indicate that sacituzumab tirumotecan (sac-TMT), a novel antibody-drug conjugate, significantly improves disease control and overall survival in patients with advanced or recurrent endometrial cancer. This benefit was observed in patients whose disease had progressed after receiving platinum-based chemotherapy and immunotherapy, offering a new therapeutic option for those with limited alternatives.